Trial Profile

First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 14 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OBT 357 (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man
Acronyms ARMY
Sponsors Menarini

Most Recent Events

12 Aug 2024 Interventional Study Model changed from Single Group Assignment to Sequential Assignment.
05 Jul 2021 Status changed from active, no longer recruiting to discontinued.
11 May 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Jun 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com